Shots:
- Valo Health has entered into a strategic collaboration with Merck KGaA to accelerate therapeutic discovery for Parkinson’s disease & related neurodegenerative disorders
- As per the deal, Valo Health will receive an upfront & milestone payment totaling over $3B, with royalties & R&D funding
- Collaboration will use Valo’s AI-enabled human causal biology platform to discover & validate new disease targets, while its closed-loop discovery platform will accelerate preclinical compound generation
Ref: Businesswire| Image: Valo Health & Merck KGaA | Press Release
Related News:- Biocytogen Partners with Merck KGaA to Develop Antibody-Conjugated Lipid-Based Delivery Solutions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
